JiscMail Logo
Email discussion lists for the UK Education and Research communities

Help for PHYSIO Archives


PHYSIO Archives

PHYSIO Archives


PHYSIO@JISCMAIL.AC.UK


View:

Message:

[

First

|

Previous

|

Next

|

Last

]

By Topic:

[

First

|

Previous

|

Next

|

Last

]

By Author:

[

First

|

Previous

|

Next

|

Last

]

Font:

Proportional Font

LISTSERV Archives

LISTSERV Archives

PHYSIO Home

PHYSIO Home

PHYSIO  March 2001

PHYSIO March 2001

Options

Subscribe or Unsubscribe

Subscribe or Unsubscribe

Log In

Log In

Get Password

Get Password

Subject:

Drug Industry Too Healthy?

From:

[log in to unmask]

Reply-To:

PHYSIO - for physiotherapists in education and practice <[log in to unmask]>

Date:

Sun, 11 Mar 2001 04:52:28 EST

Content-Type:

text/plain

Parts/Attachments:

Parts/Attachments

text/plain (71 lines)

The following article published in one of the world's most erudite academic
journals provides some interesting information on the supremely healthy state
of the drug industry.  Read the following extracts.

-------------------------------

New England Journal editor blasts Drug Industry

<http://www.vrp.com/BreakingNewsDetail.asp?id=416>

<At a time when high drug prices force some Americans to choose between
medicines and basic necessities, the outgoing editor of the New England
Journal of Medicine attacked the pharmaceutical industry, calling for a study
of price controls and urging new laws to curb certain business practices.

"The pharmaceutical industry is extraordinarily privileged," Marcia Angell
wrote in Thursday's issue. She said drug companies benefit enormously from
publicly funded research, tax breaks and other business advantages while
reaping big profits. "An industry so important to the public health and so
heavily subsidized and protected by the government has social
responsibilities that should not be totally overshadowed by its drive for
profits," Angell wrote in an editorial. "There needs to be a better balance
between the interests of the shareholders and those of the public."

..... The criticism came as the cost of medicine in the United States was
rising about 15 percent per year. In Maine in May legislators passed a law
that would use the state's purchasing power to cut drug prices for residents.
Similar measures were being considered, but not acted upon in California and
Vermont. Congress is working on a plan to help senior citizens and the
disabled on Medicare, the nation's health insurance program for its elderly,
pay for prescription drugs.

The rate of pharmaceutical price hikes is increasing so rapidly, Angell said,
that drug expenses "will soon surpass the spending for physicians' services"
and could outstrip the annual pricetag for hospitalizations in many health
maintenance organizations (HMOs).

Older Americans without supplemental Medicare insurance pay twice as much for
the 10 most commonly prescribed drugs as do large HMOs. U.S. consumers
"regularly pay up to twice as much as Europeans and Canadians for the same
drug," she said. Pharmaceutical companies say prices are high because drug
quality is high, drug research is expensive, and price controls in other
countries are forcing them to make up the difference here. But Angell said
many of the industry's arguments are "exaggerated or misleading," and some
are simply false.

"Over the past few years the pharmaceutical industry as a whole has been by
far the most profitable industry in the United States" with profit margins
for the top 10 drugs averaging a "stunning" 30 percent, and overall profits
at about 18.6 percent, she said. Banking ranked second at 15.8 percent.

Not only is much of the basic drug research funded by the U.S. government,
said Angell, "the industry also enjoys great tax advantages. Not only are its
research and development costs deductible, but so are its massive marketing
expenses."

Pfizer spent 39.2 percent of its revenues on marketing and administration in
1999. Pharmacia & Upjohn reportedly spend about the same, she said. The drug
companies say they need to spend money to educate doctors and the public
about their medicines.

"But to rely on the drug companies for unbiased evaluations of their products
makes about as much sense as relying on beer companies to teach us about
alcoholism," she said. "The fact is that marketing is meant to sell drugs and
the less important the drug, the more marketing it takes to sell it." >

------------------------

Dr Mel C Siff
Denver, USA
http://groups.yahoo.com/group/Supertraining/

Top of Message | Previous Page | Permalink

JiscMail Tools


RSS Feeds and Sharing


Advanced Options


Archives

August 2018
July 2018
June 2018
May 2018
April 2018
March 2018
February 2018
January 2018
December 2017
November 2017
October 2017
September 2017
August 2017
July 2017
June 2017
May 2017
April 2017
March 2017
February 2017
January 2017
December 2016
November 2016
October 2016
September 2016
August 2016
July 2016
June 2016
May 2016
April 2016
March 2016
February 2016
January 2016
December 2015
November 2015
October 2015
September 2015
August 2015
July 2015
June 2015
May 2015
April 2015
March 2015
February 2015
January 2015
December 2014
November 2014
October 2014
September 2014
August 2014
July 2014
June 2014
May 2014
April 2014
March 2014
February 2014
January 2014
December 2013
November 2013
October 2013
September 2013
August 2013
July 2013
June 2013
May 2013
April 2013
March 2013
February 2013
January 2013
December 2012
November 2012
October 2012
September 2012
August 2012
July 2012
June 2012
May 2012
April 2012
March 2012
February 2012
January 2012
December 2011
November 2011
October 2011
September 2011
August 2011
May 2011
April 2011
March 2011
February 2011
January 2011
December 2010
October 2010
September 2010
August 2010
July 2010
May 2010
April 2010
March 2010
February 2010
January 2010
December 2009
November 2009
October 2009
September 2009
July 2009
June 2009
May 2009
April 2009
March 2009
February 2009
December 2008
November 2008
October 2008
September 2008
August 2008
July 2008
June 2008
May 2008
April 2008
March 2008
February 2008
January 2008
December 2007
November 2007
October 2007
September 2007
August 2007
July 2007
June 2007
May 2007
April 2007
March 2007
February 2007
January 2007
December 2006
November 2006
October 2006
September 2006
August 2006
July 2006
June 2006
May 2006
April 2006
March 2006
February 2006
January 2006
December 2005
November 2005
October 2005
September 2005
August 2005
July 2005
June 2005
May 2005
April 2005
March 2005
February 2005
January 2005
December 2004
November 2004
October 2004
September 2004
August 2004
July 2004
June 2004
May 2004
April 2004
March 2004
February 2004
January 2004
December 2003
November 2003
October 2003
September 2003
August 2003
July 2003
June 2003
May 2003
April 2003
March 2003
February 2003
January 2003
December 2002
November 2002
October 2002
September 2002
August 2002
July 2002
June 2002
May 2002
April 2002
March 2002
February 2002
January 2002
December 2001
November 2001
October 2001
September 2001
August 2001
July 2001
June 2001
May 2001
April 2001
March 2001
February 2001
January 2001
December 2000
November 2000
October 2000
September 2000
August 2000
July 2000
June 2000
May 2000
April 2000
March 2000
February 2000
January 2000
December 1999
November 1999
October 1999
September 1999
August 1999
July 1999
June 1999
May 1999
April 1999
March 1999
February 1999
January 1999
December 1998
November 1998
October 1998
September 1998
August 1998
July 1998
June 1998
May 1998
April 1998
March 1998


JiscMail is a Jisc service.

View our service policies at https://www.jiscmail.ac.uk/policyandsecurity/ and Jisc's privacy policy at https://www.jisc.ac.uk/website/privacy-notice

Secured by F-Secure Anti-Virus CataList Email List Search Powered by the LISTSERV Email List Manager